Pharma/fine chemicals roundup—26 August 2014
7:19 AM MDT | August 26, 2014 | By DEEPTI RAMESH
Siegfried reports a slight increase in profits
Siegfried (Zofingen, Switzerland) reports a 1.6% rise in net profits for the first six months of 2014 compared with the year-ago period, to 18.8 million Swiss francs ($20.5 million). First-half sales decreased 16%, however, to SF165.1 million. Fluctuations in currency exchange rates and raw material prices as well as the introduction of a new technology during first-half 2014 hurt sales development, Siegfried says. Profitability continued to grow as the result of cost variabilization as well as consistent cost management and efficiency-raising measures, the company says. While the volume of the active pharmaceutical ingredients (APIs) business improved, sales declined by 6.4% compared to the first half of 2013, to SF126.4 million. Exclusive synthesis contributed 57% toward sales in this division, and controlled substances accounted for 43%. Sales of drug products, representing about a quarter of total sales, declined by 37.2% compared to the first six months of 2013, Siegfried says.
AB SCIEX and Dalton collaborate to advance antibody-drug conjugate analysis
AB SCIEX (Framingham, MA) and Dalton Pharma Services (Toronto) have entered into a research collaboration to develop antibody-drug conjugate (ADC) analysis capabilities. This will include development of more definitive and comprehensive method for the identification of drug loading and position of conjugation on macromolecules. The collaboration provides AB SCIEX, a leader in life science analytical technologies, with the specialized synthetic conjugation capabilities of Dalton. “A key challenge for developing successful ADC medicines is understanding the structure and payload of the final molecule. Determining where the drug attaches to a particular antibody early in its development and the number of drug molecules on the antibody are important indicators of the likely success of a new ADC," says Tan Quach, chemistry manager at Dalton.
“Recent advances in mass spectrometry have provided a solution to answer the challenging questions in terms of understanding ADC drug development and working within a biological matrix," says Chris Radloff, v.p. at AB SCIEX. "Utilizing these molecules is difficult and by forming this partnership, ADC developers can now reduce complications, and obtain accurate results that will ultimately lead to safer, more effective therapies.”
Abbott commences tender offer to acquire generics pharmaceutical company in Chile
Abbott says it has commenced a tender offer for the previously announced acquisition of CFR Pharmaceuticals (Santiago, Chile), a branded generics pharmaceutical company. CFR, which was founded in 1922, generated sales of $768 million in 2013. CFR participates in 15 Latin American countries. Its product portfolio is well aligned with Abbott's branded generic product offerings, specifically in the areas of women's health, central nervous system, cardiovascular and respiratory diseases. In addition to leading products and a robust pipeline, the acquisition adds a number of talented employees, and R&D and manufacturing facilities in Chile, Colombia, Peru and Argentina, Abbott says. The tender offer will expire on 23 September, and the acquisition is scheduled to close in the current quarter.
Aesica appoints new product release manager
Aesica (Newcastle, UK) says it has appointed Adam Burgess to the position of product release manager. Based at Queenborough, UK, Burgess has responsibility for pharmaceutical quality assurance across the site. A key function is to ensure on time release of products. He will work closely with production personnel at the site, with the specific goal of ensuring that operational departments build quality into their processes and organizational structures, Aesica says. Burgess will report to Christine Ernst, the site head of quality at Aesica Queenborough. Previously, Burgess held the position of manager/defective medicines report centre and import notification at the Medicines and Healthcare Products Regulatory Agency (MHRA; London). Prior to that, he also worked as a manager/preclinical quality assurance at GlaxoSmithKline.
Beyond IHS Chemical Week:
Macfarlan Smith fined $12,000 after accident at API plant
Opiate API manufacturer Macfarlan Smith (Edinburgh, UK) has been fined £12,000 for failing to ensure the safety of an employee injured at its plant in Scotland in 2011. The firm — part of UK chemicals and precious metal company Johnson Matthey — accepted the fine and admitted breaching the 1974 Health & Safety at Work Act in a hearing at the Edinburgh Sheriff Court.